Bright Minds Biosciences Inc. (DRUG) |
|
0.7601 0 (0.01%)
|
01-27 15:59 |
|
Open: |
0.755 |
Pre. Close: |
0.76 |
|
High:
|
0.78 |
Low:
|
0.7483 |
|
Volume:
|
144,704 |
Market Cap:
|
14(M) |
|
|
|
Technical analysis |
as of: 2023-01-27 4:43:55 PM |
|
Overall:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
| Target: |
Six months: 0.96  One year: 1.05 |
| Support: |
Support1: 0.69 Support2: 0.58 |
| Resistance: |
Resistance1: 0.82 Resistance2: 0.89 |
| Pivot: |
0.79 |
| Moving Average: |
MA(5): 0.76 MA(20): 0.79
MA(100): 1.04 MA(250): 1.22 |
| MACD: |
MACD(12,26): -0.1 Signal(9): -0.1  |
| Stochastic oscillator: |
%K(14,3): 9.3 %D(3): 13.6 |
| RSI: |
RSI(14): 38.7 |
| 52-week: |
High: 4.75 Low: 0.69 |
| Average Vol(K): |
3-Month: 261 (K) 10-Days: 186 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ DRUG ] has closed above bottom band by 17.5%. Bollinger Bands are 76.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 69 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
0.78 - 0.79 |
0.79 - 0.79 |
|
Low:
|
0.74 - 0.74 |
0.74 - 0.75 |
|
Close:
|
0.75 - 0.76 |
0.76 - 0.77 |
|
Company Description |
|
Bright Minds Biosciences Inc., a pre-clinical biosciences company, develops 5-HT (serotonin) medicines to improve the lives of patients with severe and life-altering diseases. Its portfolio of selective 5-HT receptor agonists comprises 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry. The company has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. The company was incorporated in 2019 and is headquartered in Vancouver, Canada. |
Headline News |
Sun, 29 Jan 2023
What it’s like to take Ozempic or Wegovy for weight loss or diabetes - NBC News
Sun, 29 Jan 2023
Why vending machines with a lifesaving drug are growing in the US - The Guardian US
Sat, 28 Jan 2023
Mayetta woman arrested on drug charges - Topeka - WIBW
Sat, 28 Jan 2023
Spanish police seize cocaine worth $114 million from cattle ship - Reuters.com
Sat, 28 Jan 2023
Amazon's RxPass and Mark Cuban's Cost Plus Drug Company aren't as revolutionary for buying cheap generic drugs ... - Slate
Sat, 28 Jan 2023
How a Drug Company Made $114 Billion by Gaming the U.S. Patent System - The New York Times
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
19 (M) |
| Shares Float |
14 (M) |
|
% Held by Insiders
|
36 (%) |
|
% Held by Institutions
|
3.3 (%) |
|
Shares Short
|
819 (K) |
|
Shares Short P.Month
|
933 (K) |
Stock Financials |
|
EPS
|
-1.04 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0.6 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-57.4 |
|
Return on Equity (ttm)
|
-100 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
0 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-14 (M) |
|
Levered Free Cash Flow
|
-8 (M) |
Stock Valuations |
|
PE Ratio
|
-0.74 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
1.26 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-1.05 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
